Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Correction re NICE Guidance

28th Oct 2009 14:08

RNS Number : 5262B
Ultrasis PLC
28 October 2009
 

Ultrasis plc ("Ultrasis" or "the Company")

Correction to announcement released at 12.09pm on 28 October 2009 under 

RNS number 5160B.

The announcement stated that the Company intends to announce its full year results for the financial year to 31st July 2008, on Wednesday 4th November. This should be full year results for the financial year to 31st July 2009. No other corrections have been made to the announcement and the corrected version appears again in full below.

------------------------------------------------------------------------------------------------------

NICE guidance recommends CCBT as a mainstream treatment of choice for treating depression

Ultrasis plc is pleased to announce that from today computerised cognitive behavioural therapy (CCBT) has been recognised as a mainstream treatment of choice for mild and moderate depression in two newly released Depression Guidelines (for depression in adults and depression with a chronic physical health problem). These new guidelines replace the previous technical appraisal (TA097 - Feb 2006) on CCBT and become the authoritative documents on how people suffering with depression should be treated.

The Directors believe that this further recognition by NICE should help Ultrasis continue to grow the market in which "Beating the Blues" has already demonstrated its effectiveness.

Welcoming this announcement Nigel Brabbins CEO at Ultrasis said 

"We have pioneered the use of computer delivered treatment for depression and invested significant resources in becoming the market leader, and this announcement vindicates all that we have done to date and opens up many new opportunities for the Company. We see this new guidance as confirmation that Beating the Blues has demonstrated both cost and clinical effectiveness and with more than 75% of Primary Care Trusts already using Beating the Blues to treat their patients we believe that it will encourage wider adoption to help increase patient choice and improve access to treatment."

Dr Charlie Martin, Clinical Director added 

"The new NICE Guidelines have broadened the application of CCBT to include people with 'persistent sub threshold depressive symptoms' ( as well as those with mild and moderate depression) and also include treatment of depression in adults who have chronic physical health problems. This will significantly increase the numbers of people for which Beating the Blues is an appropriate treatment. There may be up to twice as many people with sub threshold depressive symptoms as there are people with mild and moderate depression and the prevalence of depression in people with a chronic physical health problem is also much higher ''. He added "We have significantly improved Beating the Blues since the original NICE Guidance was published in 2006, such as ensuring that it is encrypted to meet stringent NHS standards, and providing easy ways for the clinician to monitor patient progress. We also continue to gather evidence on the programme's benefits across a wide range of health needs and this includes people with physical health problems. We are confident that the track record of Beating the Blues will keep it the treatment of choice within the NHS."

Announcement of Preliminary Results

The Company intends to announce its full year results for the financial year to 31st July 2009, on Wednesday 4th November.

For further information please contact:

Ultrasis plc

Nigel Brabbins, Chief Executive 

+44 (0) 20 7566 3900

[email protected]

Geoff Nash, 

FinnCap

Nominated Advisor and Joint Broker 

+44 (0) 207600 1658

John Webb, 

Marshall Securities

Joint Broker

+44 (0) 207 490 3788 

Media Enquiries

JBP

Karen White/Rebecca Hosgood

+44 (0) 117 9073400

[email protected] ; [email protected]

or visit:

 www.ultrasis.com

www.getfitwellness.com

www.sodexoUSA.com

Notes to Editors

Ultrasis plc is a healthcare company with core expertise in health, psychology, software development and programme management. The Company delivers computerised healthcare products to the NHS, the corporate sector and other healthcare providers in the UK and internationally.

Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy and interactive multimedia, and is the world leader in this field. The products help people tackle stress, anxiety and depression, and a full spectrum of related conditions.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALEPAEENFFE

Related Shares:

Ultrasis Plc
FTSE 100 Latest
Value8,275.66
Change0.00